Celgene Corporation (CELG) 64.60 -0.70

Trade CELG
NOW!
Last Trade:64.32Short Ratio:3.30
Last Trade Time:4:00pmDay Range:63.56 - 65.79
Ask:64.60Year Range:36.90 - 65.79
Bid:63.78One Year Target:67.52
Open:65.70Exchange:NasdaqNM
Volume:5393787EBITDA:968.0M
Prev. Close:65.02Market Cap:29.570B
50 Day Moving:59.6183Div Yield:
200 day moving:55.8794PE:39.12

Related RealMoney articles from TheStreet.com

Sirius XM, Chordiant Software: Midday Volume Plays
'Fast Money' Recap: Next Moves
InterMune Surges on FDA Drug Review
Apple, Little Understood, Is Best-Run Company
Anadarko, Celgene, Cognizant Hit Highs

Celgene Corporation to Present at the Barclays Capital 2010 Global Healthcare Conference

Posted on 03/18/10 at 7:33am
SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Barclays Capital 2010 Global Healthcare Conference on Wednesday, March 24, 2010 at 10:45 a.m.
Click here to read the rest of the article

Celgene Upward Momentum Looks to Continue (CELG)

Posted on 03/17/10 at 6:18pm
SmarTrend identified an Uptrend for Celgene (NASDAQ: CELG) on February 18, 2010 at $59.74. In approximately 4 weeks, Celgene has returned 8.3% as of today's recent price of $64.68.
Click here to read the rest of the article

Top Takeover Targets In The Biotechnology Sector This Year (VRTX, AUXL, CELG, ITMN, GENZ)

Posted on 03/09/10 at 9:09pm
Analysts at Morningstar have compiled a list of top takeover targets in the biotechnology sector this year. Morningstar said that it weighed drug portfolio strength, fit with potential partners, profit-boosting power, and financial health in assessing the chances of a takeover.
Click here to read the rest of the article
Posted in

Guy Adami is Bullish On CELG And Bearish On RIG

Posted on 03/09/10 at 9:08pm
Guy Adami said on CNBC's Fast Money that he recommends Celgene (NASDAQ: CELG) to investors interested in biotech stocks. Celgene (CELG) added 0.28% today and closed at $61.76, with a turnover of 1.59M traded shares.
Click here to read the rest of the article
Posted in

Symposium to Affirm Conditions Leading to New EHSI Business Model

Posted on 03/01/10 at 12:09pm
HOUSTON--(BUSINESS WIRE)-- Emerging Healthcare Solutions, Inc. (Pink Sheets: EHSI) was bolstered by news that the Company’s view of the current emerging healthcare technology financing market is to be paralleled at the Emerging Medical Technology Symposium this Wednesday.
Click here to read the rest of the article

Fast Money Trades (DO, APA, CELG, DB)

Posted on 02/26/10 at 6:25pm
In the first 20 minutes of the show, the Fast Money traders offered up a number of interesting trades and analysis. Guy Adami said that Celgene (NASDAQ: CELG) is still the best company in the biotech space.
Click here to read the rest of the article
Posted in

Celgene Corporation to Present at Two Upcoming Investor Conferences

Posted on 02/25/10 at 8:32am
SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced its presentations at two upcoming investor conferences will be webcast live and will be available in the investor relations section of the company’s Web site at
Click here to read the rest of the article

Stocks That Created New 52-Week Highs (ATRM, AIPC, ATLS, CPLA, CELG)

Posted on 02/18/10 at 4:06pm
Aetrium Incorporated (NASDAQ: ATRM) shares jumped 5.26% to create a new 52-week high of $3. ATRM markets electromechanical equipment used by the semiconductor industry to handle and test integrated circuits (ICs).
Click here to read the rest of the article
Posted in

Celgene Moving On High Volume (CELG)

Posted on 02/18/10 at 1:42pm
Biotech name, Celgene (NASDAQ: CELG) is trading higher today on heavier than normal volume. The stock is now trading very close to its 52 week high of $60.50. Currently the shares have moved 1.25% higher on the day to $59.79. On the session, 3.13 million shares have already changed hands. Average daily volume is 3.85 million shares.
Click here to read the rest of the article
Posted in

Healthcare Industry Update (CI, PFE, WLP, CEPH, CELG)

Posted on 02/17/10 at 3:04pm
Analyst John L. Sullivan at Leerink Swann has released an update on the Healthcare industry. According to Leerink Swann, the fourth-quarter results at companies in the healthcare sector have shown strong fundamentals. Leerink Swann believes that the relative stock valuation in the sector is attractive, and the near-term healthcare reform worries are overblown.
Click here to read the rest of the article
Posted in